The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

We have identified a macrophage population "Mrep" that plays an essential role in muscle repair. However, in Fibrodysplasia ossificans progressiva (FOP), Mrep functions as a pathogenic cell that ...

Musculoskeletal disorders are a primary cause of disability worldwide, especially in aging societies like Japan. As individuals age, reductions in muscle mass and physical activity weaken the body's ...

BELLMAWR, New Jersey (WPVI) -- A young South Jersey boy has one wish for his birthday this year, and that is to help raise money for those living with a rare disease. Nine-year-old AJ Gonzales of ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

Fibrodysplasia Ossificans Progressiva: Symptoms, Complications and Diagnosis: By Shreoshree Chakrabarty There are distinct reasons for the unique characteristics of muscle and bone. Muscle provides ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If ...

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification ...

Clementia Pharmaceuticals, Inc. today announced that it has commenced enrollment in the second part (Part B) of its natural history study in patients with fibrodysplasia ossificans progressiva (FOP), ...

A rare medical condition, Fibrodysplasia Ossificans Progressiva (FOP), also known as 'Stone Man Syndrome,' has been identified for the first time in Jaisalmer, Rajasthan. A 9-year-old child is ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma ...